Conversely, a post-mortem study of mGlu5 binding saw increases in mGlu5 expression in the frontal cortex and hippocampus of severe AD patients as compared to controls (5.2-fold and 2.5-fold respectively) (Müller Herde et al., 2019). Here, GRM5 is linked to Alzheimer disease.